Primary and Secondary Prevention Strategy for Cardiovascular Disease in Diabetes Mellitus

Cardiology Clinics

Volumn 29, Issue 1, 2011, Pages 47-70

  Srikanth, Sundararajan ^a   Deedwania, Prakash ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cardiovascular disease; Diabetes mellitus; Primary prevention

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE PLUS BENAZEPRIL; ATORVASTATIN; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; GEMFIBROZIL; GLICLAZIDE; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE PLUS PERINDOPRIL; INSULIN; LOSARTAN; METFORMIN; PIOGLITAZONE; PLACEBO; PRAVASTATIN; RAMIPRIL; ROSIGLITAZONE; SIMVASTATIN; SULFONYLUREA;

ADD ON THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETOGENESIS; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; DYSLIPIDEMIA; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; LIFESTYLE MODIFICATION; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; THROMBOSIS; WEIGHT REDUCTION;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS; HUMANS; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; SECONDARY PREVENTION;

EID: 78751622131     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2010.11.004     Document Type: Review

References (86)

1. Wild S., Roglic G., Green A., et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
2. CDC National Health and Nutrition Examination Survey 1999-2000 data files Available at:, Accessed December 9, 2010. http://www.cdc.gov/nchs/nhanes/nhanes1999-2000/nhanes99_00.htm.
3. International Diabetes Federation IGT/IFG consensus statement. Report of an expert consensus workshop, August 1-4, 2001. Stoke Poges, United Kingdom. Impaired glucose tolerance and impaired fasting glycemia: the current status on definition and intervention. Diabet Med 2002, 19:708-723.
4. Haffner S.M., Lehto S., Ronnemaa T., et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229-234.
5. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
6. Saydah S.H., Eberhardt M.S., Loria C.M., et al. Age and the burden of death attributable to diabetes in the United States. Am J Epidemiol 2002, 156:714-719.
7. Bhatt D.L., Eagle K.A., Ohman E.M., et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 2010, 304(12):1350-1357.
8. Schramm T.K., Gislason G.H., Kober L., et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation 2008, 117:1945-1954.
9. Spencer E.A., Pirie K.L., Stevens R.J., et al. Diabetes and modifiable risk factors for cardiovascular disease: the prospective Million Women Study. Eur J Epidemiol 2008, 23(12):793-799.
10. Sarwar N., Gao P., et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010, 375(9733):2215-2222. Emerging risk factors collaboration.
11. Gu K., Cowie C.C., Harris M.I. Diabetes and decline in heart disease mortality in US adults. JAMA 1999, 281:1291-1297.
12. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002, 287:356-359.
13. Fagan T.C., Deedwania P.C. The cardiovascular dysmetabolic syndrome. Am J Med 1998, 105(1A):77S-82S.
14. Ford E.S., Li C., Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care 2008, 31:1898.
15. Sattar N., McConnachie A., Shaper A.G., et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 2008, 371:1927.
16. Abbasi F., McLaughlin T., Lamendola C., et al. The relationship between glucose disposal in response to physiological hyperinsulinemia and basal glucose and free fatty acid concentrations in healthy volunteers. J Clin Endocrinol Metab 2000, 85:1252-1254.
17. Taskinen M.R., Smith U. Lipid disorders in NIDDM: implications for treatment. J Intern Med 1998, 244:361-370.
18. Garg A. Treatment of diabetic dyslipidemia. Am J Cardiol 1998, 81:47B-51B.
19. Veniant M.M., Sullivan M.A., Kim S.K., et al. Defining the atherogenicity of large and small lipoproteins containing apolipoprotein B100. J Clin Invest 2000, 106:1501-1510.
20. Stamler J., Vaccaro I., Neaton J.D., et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993, 16:434-444.
21. Turner R.C., Millns H., Neil H.A., et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998, 316:823-828.
22. Garg A., Grundy S.M. Management of dyslipidemia in NIDDM. Diabetes Care 1990, 13:153-169.
23. Pyorola K., Pederson T.R., Kjekshus J., et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a sub-group analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997, 20:614-620.
24. Goldberg R.B., Mellies M.J., Sacks F.M., for the CARE investigators, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol and recurrent events (CARE) trial. Circulation 1998, 98:2513-2519.
25. Shepherd J., Barter P., Carmena R., et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006, 29:1220-1226.
26. Shepherd J., Kastelein J.P., Bittner V.A., Treating to New Targets Steering Committee and Investigators, et al. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clin Proc 2008, 83(8):870-879.
27. Collins R., Armitage J., Parish S., et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003, 361(9374):2005-2016.
28. Colhoun H.M., Betteridge D.J., Durrington P.N., CARDS investigators, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicenter randomized placebo-controlled trial. Lancet 2004, 364(9435):685-696.
29. Koskinen P., Manninen V., Huttunen J.K., et al. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992, 15:820-825.
30. Keech A., Simes R.J., Barter P., FIELD Study Investigators, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet 2005, 366:1849-1861.
31. The ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010, 362:1563-1574.
32. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
33. Grundy S.M., Cleeman J.I., Bairey Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239.
34. American Diabetes Association Standards of medical care in diabetes-2010. Diabetes Care 2010, 33(Suppl 1):S11-S61.
35. Ferrannini E., Buzzigoli G., Bonadona R. Insulin resistance in essential hypertension. N Engl J Med 1987, 317:350-357.
36. Swislocki A.L., Hoffman B.B., Raven G.M. Insulin resistance, glucose intolerance and hyperinsulinemia in patients with hypertension. Am J Hypertens 1989, 2:419-423.
37. UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications of type 2 diabetes: UKPDS 38. Br Med J 1998, 317:703-713.
38. Hansson L., Zanchetti A., Carruthers S.G., et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 1998, 351:1755-1762.
39. The ACCORD study group Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010, 362:1575-1585.
40. Patel A., MacMahon S., et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007, 370(9590):829-840. ADVANCE Collaborative Group.
41. Wright J.T., Jones D.W., Green L.A., et al. The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 Report. JAMA 2003, 289:2560-2571.
42. Bakris G.L., Williams M., Dworkin L., et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000, 36(3):646-661.
43. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE Study and MICRO-HOPE substudy. Lancet 2000, 355:253-259. [published correction appears in Lancet 2000;356:850].
44. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney disease outcome quality initiative. Am J Kidney Dis 2002, 39(Suppl 1):S1-S266.
45. Weber M.A., Bakris G.L., Jamerson K., et al. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol 2010, 56:77-85.
46. United Kingdom Prospective Diabetes Study Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
47. United Kingdom Prospective Diabetes Study Group Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854-865.
48. Khaw K.T., Wareham N., Luben R., et al. Glycated hemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ 2001, 322(7277):15-18.
49. DECODE Study Group, European Diabetes Epidemiology Group Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases?. Diabetes Care 2003, 26(3):688-696.
50. The Action to Control Cardiovascular Risk in Diabetes Study Group Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559.
51. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572. The ADVANCE Collaborative Group.
52. Dormandy J.A., Charbonnel B., Eckland D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279-1289.
53. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
54. Home P.D., Pocock S.J., Beck-Nielsen H., et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009, 373:2125-2135.
55. Nissen S.E., Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010, 170(14):1191-1201.
56. Nathan D.M., Buse J.B., Davidson M.B., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203.
57. Holman R.R., Paul S.K., Bethel A., et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
58. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet 2002, 357:89-95. Collaborative Group of the Primary Prevention Project.
59. Baigent C., Blackwell L., et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009, 373:1849-1860. Antithrombotic Trialists' (ATT) Collaboration.
60. ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. JAMA 1992, 268:1292-1300.
61. Belch J., MacCuish A., Campbell I., et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomized placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008, 337:a1840.
62. Wolff T., Miller T., Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009, 150:405-410.
63. US Preventive Services Task Force Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009, 150:396-404.
64. De Berardis G., Sacco M., Evangelista V., et al. ACCEPT-D Study Group. Aspirin and simvastatin combination for cardiovascular events prevention trial in diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials 2007, 8:21.
65. British Heart Foundation ASCEND: a study of cardiovascular events in diabetes Available at:, Accessed September 19, 2010. http://clinicaltrials.gov/ct2/show/NCT00135226.
66. Pignone M., Alberts M.J., Colwell J.A., et al. Aspirin for primary prevention of cardiovascular events in people with diabetes. J Am Coll Cardiol 2010, 55(25):2878-2886.
67. Collaboration meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324:71-86. Antithrombotic Trialists' Collaboration.
68. Pi-Sunyer X., Blackburn G., Brancati F.L., et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD trial. Diabetes Care 2007, 30:1374-1383.
69. Mozaffarian D., Rimm E.B. Fish intake, contaminants and human health: evaluating the risks and the benefits. JAMA 2006, 297:1885-1899.
70. Buse J.B., Ginsberg H.N., Bakris G.L., et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007, 115(1):114-126.
71. Chobanian A.V., Bakris G.L., Black H.R., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289(19):2560-2572.
72. Pi-Sunyer F.X., Dietz W.H., Becker D.M. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report 1998, National Heart, Lung, and Blood Institute, Bethesda (MD).
73. Gaede P., Vedel P., Larsen N., et al. Mutlifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383-393.
74. Lauritzen T., Griffin S., Borch-Johnsen K., et al. The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with type 2 diabetes detected by screening. Int J Obes Relat Metab Disord 2000, 24(Suppl 3):S6-S11.
75. Janssen P.G., Gorter K.J., Stolk R.P., et al. Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type 2 diabetes: 1-year data from the ADDITION Netherlands study. Br J Gen Pract 2009, 59:43-48.
76. Gaede P., Valentine W.J., Palmer A.J., et al. Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study. Diabetes Care 2008, 31:1510-1515.
77. Hoerger T.J., Zhang P., Segel J.E., et al. Improvements in risk factor control among persons with diabetes in the United States: evidence and implications for remaining life expectancy. Diabetes Res Clin Pract 2009, 86:225-232.
78. Hu F.B., Manson J.E., Stampfer M.J., et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001, 345(11):790-797.
79. Leal J., Gray A.M., Clarke P.M. Development of life-expectancy tables for people with type 2 diabetes. Eur Heart J 2009, 30:834-839.
80. Lindstrom J., Eriksson J.G., Valle T.T., et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. J Am Soc Nephrol 2003, 14:S108-S113.
81. The DPP Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
82. Chiasson J.L., Josse R.G., Gomis R., et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002, 359:2072-2077.
83. Knowler W.C., Fowler S.E., Hamman R.F., et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009, 374(9702):1677-1678.
84. Haffner S.M., Alexander C.M., Cook T.J., et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999, 159:2661-2667.
85. Keech A., Colquhoun D., Best J., et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 2003, 26:2713-2721.
86. Tenenbaum A., Motro M., Fisman E.Z., et al. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005, 165:1154-1160.